» Articles » PMID: 37559575

Higher Levels of Minimal Residual Disease in Peripheral Blood Than Bone Marrow Before 1st and 2nd Relapse/regrowth in a Patient with High‑risk Neuroblastoma: A Case Report

Abstract

More than half of patients with high-risk neuroblastoma (HR-NB) experience relapse/regrowth due to the activation of chemoresistant minimal residual disease (MRD). MRD in patients with HR-NB can be evaluated by quantitating neuroblastoma-associated mRNAs (NB-mRNAs) in bone marrow (BM) and peripheral blood (PB) samples. Although several sets of NB-mRNAs have been shown to possess a prognostic value for MRD in BM samples (BM-MRD), MRD in PB samples (PB-MRD) is considered to be low and difficult to evaluate. The present report describes an HR-NB case presenting higher PB-MRD than BM-MRD before 1st and 2nd relapse/regrowth. A 3-year-old female presented with an abdominal mass, was diagnosed with HR-NB, and treated according to the nationwide standard protocol for HR-NB. Following systemic induction and consolidation therapy with local therapy, the patient achieved complete remission but experienced a 1st relapse/regrowth 6 months after maintenance therapy. The patient partially responded to salvage chemotherapy and anti-GD2 immunotherapy but had a 2nd relapse/regrowth 14 months after the 1st relapse/regrowth. Consecutive PB-MRD and BM-MRD monitoring revealed that PB-MRD was lower than BM-MRD at diagnosis (100 times) and 1st and 2nd relapse/regrowth (1,000 and 3 times) but became higher than BM-MRD before 1st and 2nd relapse/regrowth. The present case highlights that PB-MRD can become higher than BM-MRD before relapse/regrowth of patients with HR-NB.

References
1.
Beiske K, Ambros P, Burchill S, Cheung I, Swerts K . Detecting minimal residual disease in neuroblastoma patients-the present state of the art. Cancer Lett. 2005; 228(1-2):229-40. DOI: 10.1016/j.canlet.2005.02.053. View

2.
Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K . Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol. 2002; 24(8):613-21. DOI: 10.1097/00043426-200211000-00004. View

3.
Viprey V, Gregory W, Corrias M, Tchirkov A, Swerts K, Vicha A . Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study. J Clin Oncol. 2014; 32(10):1074-83. DOI: 10.1200/JCO.2013.53.3604. View

4.
Thwin K, Ishida T, Uemura S, Yamamoto N, Lin K, Tamura A . Level of Seven Neuroblastoma-Associated mRNAs Detected by Droplet Digital PCR Is Associated with Tumor Relapse/Regrowth of High-Risk Neuroblastoma Patients. J Mol Diagn. 2019; 22(2):236-246. DOI: 10.1016/j.jmoldx.2019.10.012. View

5.
Maris J, Hogarty M, Bagatell R, Cohn S . Neuroblastoma. Lancet. 2007; 369(9579):2106-20. DOI: 10.1016/S0140-6736(07)60983-0. View